Four Wan Pharmaceutical Holdings Group Limited (hereinafter referred to as “Four Yuan Pharmaceuticals”) has published its 2023 Annual Report and Circular on 29 April 2024, as well as the 2023 Environmental, Social and Governance Report. Both Chinese and English versions of these documents are available on the Company's website and on the HKEX's easily disclosed website. The Company will send a notice of posting of the website version of the relevant communication document to non-registered holders by e-mail or by mail. Quadruple Pharmaceuticals encourages shareholders to provide email addresses through intermediaries to support electronic communications. If a shareholder wishes to receive a printed newsletter, they may complete the application form and send it back to Jujia Securities Registration Company Limited. The Chairman and Executive Director of the Company issued a notice on behalf of the Board of Directors.

Four Wan Pharmaceutical Holdings Group Limited (hereinafter referred to as “Four Yuan Pharmaceuticals”) has published its 2023 Annual Report and Circular on 29 April 2024, as well as the 2023 Environmental, Social and Governance Report. Both Chinese and English versions of these documents are available on the Company's website and on the HKEX's easily disclosed website. The Company will send a notice of posting of the website version of the relevant communication document to non-registered holders by e-mail or by mail. Quadruple Pharmaceuticals encourages shareholders to provide email addresses through intermediaries to support electronic communications. If a shareholder wishes to receive a printed newsletter, they may complete the application form and send it back to Jujia Securities Registration Company Limited. The Chairman and Executive Director of the Company issued a notice on behalf of the Board of Directors.